Latest Period
n/a
Security Snapshot
Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) Institutional Ownership
CUSIP: 45339J105
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.46
- Type / Class
- Equity / Common Stock, $0.01 par value
- Symbol
- INDP on Nasdaq
- Shares outstanding
- 111,087,302
- Price per share
- $0.46
- Price from insider filings
- $0.46
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value is tracked under CUSIP 45339J105.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 17 to 0 between Q1 2025 and Q2 2025.
- Reported value moved from $353,682 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Schedule 13D/13G
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 45339J105?
CUSIP 45339J105 identifies INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45339J105:
Significant Owners of Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Yao Yun | 38% | $19,315,860 | 41,991,000 | Yao Yun | 23 Mar 2026 | |||
| Lazar David E. | 48% | -51% | $949,440 | -$50,110,560 | 2,064,000 | -98% | Lazar David E. | 23 Mar 2026 |
| YA II PN, Ltd. | 10% | $705,458 | 1,410,916 | YA II PN, Ltd. | 13 Feb 2025 | |||
| Meckler Jeffrey A | 13% | $125,627 | 273,103 | Jeffery A. Meckler | 22 Dec 2025 | |||
| Newman Michael James | 5.4% | $53,154 | 115,552 | Newman Michael James | 22 Dec 2025 |
Institutional Holders of Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$353,682 | $0.46 | 0 |
| 2025 Q1 | 643,262 | $353,682 | +$16,672 | $0.55 | 17 |
| 2024 Q4 | 638,409 | $539,564 | +$18,707 | $0.84 | 19 |
| 2024 Q3 | 605,020 | $750,238 | +$5,985 | $1.24 | 17 |
| 2024 Q2 | 599,915 | $1,262,320 | +$23,925 | $2.12 | 21 |
| 2024 Q1 | 587,768 | $1,314,120 | -$24,471 | $2.24 | 17 |
| 2023 Q4 | 602,239 | $1,058,915 | +$56,020 | $1.76 | 18 |
| 2023 Q3 | 570,529 | $1,569,014 | -$25,658 | $2.76 | 16 |
| 2023 Q2 | 583,740 | $1,109,616 | +$8,428 | $1.91 | 15 |
| 2023 Q1 | 579,339 | $1,079,449 | -$60,057 | $1.85 | 15 |
| 2022 Q4 | 576,419 | $838,524 | +$5,682 | $1.45 | 16 |
| 2022 Q3 | 566,356 | $1,222,000 | +$141,749 | $2.17 | 12 |
| 2022 Q2 | 500,710 | $1,306,000 | -$3,185,888 | $2.61 | 12 |
| 2022 Q1 | 1,687,829 | $6,751,000 | -$661,036 | $4.00 | 9 |
| 2021 Q4 | 1,836,196 | $10,466,000 | +$6,508,484 | $5.70 | 11 |
| 2021 Q3 | 541,295 | $4,239,000 | +$4,239,000 | $7.83 | 9 |